Barclays PLC Acquires 84,136 Shares of Organon & Co. (NYSE:OGN)

Barclays PLC boosted its holdings in Organon & Co. (NYSE:OGN) by 238.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 119,483 shares of the company’s stock after buying an additional 84,136 shares during the quarter. Barclays PLC’s holdings in Organon & Co. were worth $2,285,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Prospera Private Wealth LLC acquired a new stake in shares of Organon & Co. in the 3rd quarter valued at approximately $25,000. William B. Walkup & Associates Inc. bought a new position in Organon & Co. in the 2nd quarter valued at approximately $31,000. Atlas Capital Advisors LLC boosted its position in Organon & Co. by 2,236.5% in the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock valued at $46,000 after buying an additional 2,147 shares in the last quarter. Abich Financial Wealth Management LLC grew its stake in shares of Organon & Co. by 5,646.3% during the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after buying an additional 2,315 shares during the last quarter. Finally, Rothschild Investment LLC bought a new stake in shares of Organon & Co. during the second quarter worth $54,000. Institutional investors own 77.43% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on OGN shares. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. lowered Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their price target for the company from $18.00 to $20.00 in a research note on Friday, September 6th.

Organon & Co. Price Performance

OGN stock opened at $14.73 on Thursday. The company has a market capitalization of $3.79 billion, a P/E ratio of 2.92, a PEG ratio of 0.81 and a beta of 0.75. The company has a fifty day moving average price of $15.92 and a 200-day moving average price of $18.83. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 52-week low of $13.65 and a 52-week high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same period in the prior year, the business earned $0.78 earnings per share. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. As a group, equities analysts expect that Organon & Co. will post 3.89 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 7.60%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s payout ratio is presently 22.22%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.